Management of Lipids in Patients with Diabetes

被引：10

作者：

Mbue, Ngozi D. ^{[1
,2
,3
]}

Mbue, John E. ^{[2
]}

Anderson, Jane A. ^{[1
,2
,3
]}

机构：

[1] Hlth Sci Res & Dev Ctr Innovat Qual Effectiveness, 152,2002 Holcombe Blvd, Houston, TX 77030 USA

[2] Michael E DeBakey VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA

[3] Baylor Coll Med, Houston, TX 77030 USA

来源：

NURSING CLINICS OF NORTH AMERICA | 2017年 / 52卷 / 04期

关键词：

Diabetes; Lipids; Nursing; Practice applications; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN PARTICLES; CARDIOVASCULAR-DISEASE; LDL CHOLESTEROL; COLESEVELAM HYDROCHLORIDE; PRIMARY PREVENTION; DOUBLE-BLIND; APOLIPOPROTEIN-B; GLYCEMIC CONTROL; ARTERY-DISEASE;

D O I：

10.1016/j.cnur.2017.07.009

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Abnormal lipids, sometimes referred to as diabetes dyslipidemia, is a common condition in patients with diabetes. With the increasing number of patients with abnormal lipids, especially those with type 2 diabetes, health care practitioners, including nurses, must properly manage patients with diabetes as well as abnormal lipids. This article examines the pathophysiology of abnormal lipids, the management of abnormal lipids, and the lipid goals for patients with diabetes. Last, this article discusses pharmacologic and nonpharmacologic therapies and the role of primary care providers and nurses in the management of abnormal lipids.

引用

页码：605 / +

页数：17

共 87 条

[1]

AHA/ACC, 2013, CHOL TREATM GUID NOV

[2] Introduction [J].

不详 .

DIABETES CARE, 2017, 40 :S1-S130

[3] Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J].

Athyros, VG ;

Papageorgiou, AA ;

Athyrou, VV ;

Demitriadis, DS ;

Kontopoulos, AG .

DIABETES CARE, 2002, 25 (07) :1198-1202

[4]

AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917

[5] ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].

AUSTIN, MA ;

KING, MC ;

VRANIZAN, KM ;

KRAUSS, RM .

CIRCULATION, 1990, 82 (02) :495-506

[6] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[7] How Advances in Genomics are Changing Patient Care [J].

Bancroft, Elizabeth K. .

NURSING CLINICS OF NORTH AMERICA, 2013, 48 (04) :557-+

[8] Management of lipids in patients with diabetes [J].

Barnett, A .

DIABETES OBESITY & METABOLISM, 2003, 5 :S3-S9

[9] Statin Use for the Primary Prevention of Cardiovascular Disease in Adults US Preventive Services Task Force Recommendation Statement [J].

Bibbins-Domingo, Kirsten ;

Grossman, David C. ;

Curry, Susan J. ;

Davidson, KarinaW. ;

Epling, John W., Jr. ;

Garcia, Francisco A. R. ;

Gillman, Matthew W. ;

Kemper, Alex R. ;

Krist, Alex H. ;

Kurth, Ann E. ;

Landefeld, C. Seth ;

LeFevre, Michael L. ;

Mangione, Carol M. ;

Phillips, William R. ;

Owens, Douglas K. ;

Phipps, Maureen G. ;

Pignone, Michael P. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19) :1997-2007

[10] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study [J].

Bruckert, E ;

Hayem, G ;

Dejager, S ;

Yau, C ;

Bégaud, B .

CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) :403-414

← 1 2 3 4 5 6 7 8 9 →